| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 10.262 | 779 | 55.425 | 19.512 | 19.804 | 34.054 | 47.539 | 47.333 | 52.579 | 50.686 |
| Total Income - EUR | 10.262 | 779 | 55.425 | 19.512 | 19.804 | 34.054 | 47.539 | 47.333 | 52.579 | 50.686 |
| Total Expenses - EUR | 2.978 | 4.952 | 2.857 | 6.480 | 8.165 | 33.140 | 8.118 | 8.221 | 8.415 | 9.638 |
| Gross Profit/Loss - EUR | 7.284 | -4.173 | 52.568 | 13.031 | 11.638 | 913 | 39.421 | 39.112 | 44.163 | 41.048 |
| Net Profit/Loss - EUR | 6.976 | -4.188 | 51.719 | 12.836 | 11.440 | 596 | 38.946 | 38.638 | 43.638 | 40.647 |
| Employees | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Noflavidan Company Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | 15.643 | 14.128 | 67.407 | 83.278 | 95.046 | 60.990 | 60.131 | 56.329 | 61.823 | 59.576 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 15.498 | 13.724 | 67.054 | 83.233 | 91.344 | 57.559 | 59.368 | 53.946 | 59.102 | 53.558 |
| Cash | 144 | 405 | 352 | 44 | 3.702 | 3.431 | 762 | 2.383 | 2.721 | 6.017 |
| Shareholders Funds | -5.617 | -9.748 | 42.127 | 54.190 | 64.581 | 60.145 | 59.411 | 55.789 | 60.672 | 58.770 |
| Social Capital | 112 | 111 | 109 | 107 | 105 | 103 | 101 | 101 | 101 | 101 |
| Debts | 21.259 | 23.876 | 25.280 | 29.087 | 30.465 | 845 | 719 | 539 | 1.151 | 806 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4120 - 4120" | |||||||||
| CAEN Financial Year |
4120
|
|||||||||
Comments - Noflavidan Company Srl